Use of lacosamide in Lennox-Gastaut syndrome: is it too premature?

Italiano, Domenico; Aguglia, Umberto; Ferlazzo, Edoardo

doi:10.1111/ane.12252

Cited by 5 publications

(6 citation statements)

References 5 publications

(3 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This study was criticized because of some methodological issues; thus, some authors suggested to use LAC cautiously in children with LGS. To review the principal criticism/comments to this study, we recommend to read two letters to the editor that were published by Andrade-Machado et al and Italiano et al last year in Acta Neurological Scandinavica [11,12].…”

Section: Introductionmentioning

confidence: 99%

Efficacy and tolerability of add-on Lacosamide treatment in adults with Lennox–Gastaut syndrome: An observational study

Andrade-Machado

Reyes

Benjumea-Cuartas

et al. 2015

Seizure

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

Efficacy and tolerability of add-on Lacosamide treatment in adults with Lennox–Gastaut syndrome: An observational study

Andrade-Machado

Reyes

Benjumea-Cuartas

et al. 2015

Seizure

View full text Add to dashboard Cite

show abstract

“…13 worsening of seizures were observed in some patients. 15 Additional, an induction of negative myoclonus during a combined treatment with CBZ and LCM was found in one case with focal epilepsy. 16 For GGE with primary generalized seizures, some rare, underpowered, and uncontrolled trials suggest a therapeutic effect of LCM, but the evidence is weak compared to the situation in patients with focal seizures.…”

Section: Discussionmentioning

confidence: 85%

“…These medications seemed to be insufficient during the last status episode, which lasted for 120 minutes. 15 Additional, an induction of negative myoclonus during a combined treatment with CBZ and LCM was found in one case with focal epilepsy. 6-8 LCM and LZP cross the blood-brain barrier regularly within a few minutes.…”

Section: Introductionmentioning

confidence: 85%

Intravenous lacosamide for treatment of absence status epilepticus in genetic generalized epilepsy: A case report and review of literature

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Its use in LGS has been controversial, with some reports suggesting favorable clinical response, while some other reports described the worsening of seizures in LGS with the use of lacosamide. 4 5 6 7 This systematic review has been designed to assess the efficacy and safety of lacosamide in patients with LGS.…”

Section: Introductionmentioning

confidence: 99%

Efficacy and Tolerability of Lacosamide in Lennox–Gastaut Syndrome: A Systematic Review and Meta-analysis

Panda

Sharawat

Kasinathan³

et al. 2022

JNRP

View full text Add to dashboard Cite

Purpose Lennox–Gastaut syndrome (LGS) is one of the most difficult to treat childhood-onset epileptic encephalopathies. There is growing evidence that lacosamide is safe and efficacious in patients and adults with refractory epilepsy. However, the evidence regarding the efficacy of lacosamide in LGS is controversial so far. We aimed to evaluate the efficacy and tolerability of lacosamide in patients with LGS. Methods We conducted a systematic review on MEDLINE, EMBASE, COCHRANE CENTRAL, Google Scholar, and Web of Science, collating all available literature till July 31, 2020. The qualitative review included case reports, case series, and both controlled/uncontrolled trials as well as retrospective studies, but for determining pooled estimates, we only included studies with a sample size of 5 or more. The primary outcome was the efficacy of lacosamide in patients with LGS. Clinical variables related to efficacy and adverse events attributed to lacosamide were extracted from each publication. The pooled estimate of variables related to these parameters was performed using a random-effect model. Results Of the 68 items identified by the search, 14 were reviewed as full-text. Eleven articles including two prospective and six retrospective studies fulfilled eligibility criteria and described outcomes in 81 patients (42 adults, 39 children, 60% male, range—1.4–61 years). On average, 35.2%, 27.9%, 7.3%, and 29.4% patients had > 50% reduction, < 50% reduction, no change, and worsening of seizure frequency, respectively. Although 36% of patients had adverse events like somnolence, behavioral abnormalities including irritability, aggressiveness, nausea, tremor, memory problems, dizziness, gastrointestinal discomfort, vomiting, and weight loss, no serious adverse events were noted. Conclusion The evidence available in the current literature is not sufficient to support or refute the use of lacosamide in patients with LGS. Although it is one of the possible therapeutic options worth exploring in patients with LGS, caution is still necessary, as there are reports of worsening of seizure frequency in some patients.

show abstract

Use of lacosamide in Lennox-Gastaut syndrome: is it too premature?

Cited by 5 publications

References 5 publications

Efficacy and tolerability of add-on Lacosamide treatment in adults with Lennox–Gastaut syndrome: An observational study

Efficacy and tolerability of add-on Lacosamide treatment in adults with Lennox–Gastaut syndrome: An observational study

Intravenous lacosamide for treatment of absence status epilepticus in genetic generalized epilepsy: A case report and review of literature

Efficacy and Tolerability of Lacosamide in Lennox–Gastaut Syndrome: A Systematic Review and Meta-analysis

Contact Info

Product

Resources

About